Quote:
Originally Posted by Garywt
Was at the doctors today and he was telling me that 10 of his vaccinated patients got sick and 2 died. The vaccine is not mixing well with certain blood cancers, mine being one of them. So moving forward I was told to take all precautions as if I never had the vaccine. So status quo for me.
|
Quote:
Originally Posted by golfing eagles
According to the CDC, as of April 30th, out of 101 million fully vaccinated individuals, there were 10,262 breakthrough cases (=0.01%). Of these approx. 10% were hospitalized (1,026) and 2% died (205= .0002%). According to the CDC, "many" of the deaths were UNRELATED to COVID-19.
So, assuming your doctor has an average practice of 2000 patients and half of them were fully vaccinated (reasonable assumptions), he would have had 10/1000 contract COVID after vaccination (50 times the national rate) and 2/1000 die (0.2% or 1000 times the national rate). Something doesn't sound right at all.
|
This may help explain the discrepancy in numbers, from
The Lancet:
"Authorised COVID-19 vaccines are safe and effective in the general population. Given the high case fatality rate among patients with haematological conditions, prioritisation of COVID-19 vaccines for this group might appear straightforward. However, common to these vaccines is the exclusion of immunocompromised people from landmark phase 3 randomised controlled trials. Relevant exclusion criteria included the use of immunosuppressive or immunomodulatory agents, immunoglobulin or blood products, asplenia, and autoimmune conditions such as immune thrombocytopenic purpura. Most patients with haematological conditions, therefore, would have been ineligible for these trials. Until COVID-19 vaccines have been rigorously studied in this group, one must examine available data on the immune response to COVID-19 infection and non-COVID-19 vaccines to inform clinical practice and expectations.
Haematological conditions and their treatment are heterogeneous, and so the immune response to infection or vaccination is also expected to be variable. A case series reported 14 (67%) of 21 patients with chronic lymphocytic leukaemia developed IgG antibodies to SARS-CoV-2 nucleocapsid.3 Those who did not develop antibodies included both treatment-naive patients and patients receiving chronic lymphocytic leukaemia-directed therapy. The seroconversion rate among recipients of haematopoietic stem-cell transplantation and chimeric antigen receptor T-cell therapy was similar at 66% (25 of 38 patients).4 Intriguingly, B-cell lymphopenia in these patients did not preclude an antibody response to SARS-CoV-2. In acute leukaemia, antibodies against the external spike glycoprotein and internal nucleocapsid were detected in seven (88%) of eight patients.5 Besides a lower rate of antibody production, the humoral response in patients with haematological conditions is also slower than in the general population. SARS-CoV-2-specific cellular immunity in this group still needs to be characterised."
Translation for the non-professional:
We just don't know the breakthrough rate for fully vaccinated individuals with hematologic malignancies. However, since antibodies to the spike protein were measurable in only 88%, it is theoretically possible to have a breakthrough rate approaching that, but in the real world is probably much lower. However, that would still be over 100 times less effective than it is in the general population